GHZ339
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 12, 2025
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=224 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1